Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

dpoint was non-inferiority based on in-stent late lumen loss at nine months.  The in-stent late lumen loss for the Combo Stent was 0.39 +/- 0.45 mm, compared to 0.44 +/- 0.56 mm for the TAXUS stent. The results were presented late last year during the Late Breaking Clinical Trials and First Report Investigations Session at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco. The study's secondary endpoints included clinically driven TLR, binary restenosis, major adverse cardiac events (MACE) and ST rates, as well as all-cause and cardiac mortality, MI and TLF at 30 days, nine months and one through five years.

Ulf Landmesser, M.D., Ph.D., professor of cardiology and head of acute and co-head of invasive cardiology at the Cardiovascular Center, University Hospital of Zurich presented the study design for the REMEDEE OCT trial.

The REMEDEE OCT study will assess vascular healing after deployment of the Combo Stent in patients with acute coronary syndrome (ACS) with single de novo native coronary artery lesions ranging in diameter from greater than or equal to 2.5 mm to less than or equal to 3.5 mm and less than or equal to 20 mm in length. The REMEDEE OCT study, a prospective, multicenter, randomized study, will enroll 60 patients with ACS who will be randomized 1:1 to be treated with the Combo Stent versus the commercially available everolimus eluting stent. The primary endpoint of the study is the percentage of uncovered stent struts per stent at 60 days post procedure determined by OCT. Secondary clinical endpoints include stent thrombosis and major adverse cardiac events (MACE) at 30, 60, 180, 360 and 540 days. MACE is defined as a composite of death, myocardial infarction (MI), emergent coronary artery bypass surgery (CABG), or justified target lesion revascularization (TLR).

"Currently, 55 patients have been enrolled in the REMEDEE OCT study, and we anticipate to complete the enrollment in the next couple of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... San Diego, CA (PRWEB) April 24, 2015 ... San Diego and other San Diego area universities, including ... April 28 to judges from prominent local, national and ... seed funding in the 5th Annual Social Innovation ... finalists have proposed unique social venture ideas addressing a ...
(Date:4/24/2015)... , April 24, 2015 /PRNewswire/ - BioAmber Inc. ... Bayer MaterialScience as the supplier of bio-succinic acid ... bio-based polyurethanes for textile applications that Bayer MaterialScience ... has launched IMPRANIL ® eco, a series ... that reaches as high as 65%.  IMPRANIL ® ...
(Date:4/24/2015)... , April 24 , 2015 PAREXEL ... biopharmaceutical services provider, today announced that Partnerships in Clinical ... Product Management, the 2015 Clinical Innovator of the Year.  ... development team for the Company,s Perceptive MyTrials ® ... award Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Mount Dora, Florida (PRWEB) April 23, 2015 ... announced that it intends to conduct a groundbreaking ... can begin to be reversed in as little ... researchers—using the science of metabolic and nutritional medicine—will ... conditions that cripple and destroy our aging brain. ...
Breaking Biology Technology:5th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... has discovered and characterized a promising chemically modified Vitamin ... In animal studies, 2MD increases bone growth while leaving ... times the level of other compounds. , ,According to ... levels in the blood. Too little calcium can cause ...
... MADISON - A veteran television reporter recently asked me to ... expect to find jobs after they complete their education. The ... know, I would invest every penny I have in those ... Labor Day passes in Wisconsin, the question about jobs for ...
... MADISON, WI - The U.S. Department of Health and ... Regional Centers of Excellence (RCE) for Biodefense and Emerging ... with 11 other Midwestern institutions to form the Midwestern ... The Midwestern center, based at the University of Chicago ...
Cached Biology Technology:Biotech Pioneer Discusses Breakthrough in Osteoporosis Treatment 2Heres how todays Wisconsin children will find jobs tomorrow 2Heres how todays Wisconsin children will find jobs tomorrow 3UW-Madison Gets Federal Biodefense Funds 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... of Minnesota Medical School and the Brain Sciences Center ... new way to assess how brain networks act together. ... (New Mexico) led Apostolos P. Georgopoulos, M.D., Ph.D., professor ... novel way to assess the dynamic interactions of brain ...
... to develop a new device able to 'sniff out' harmful ... non-invasive wound monitor to treat patients with severe burns, skin ... a device which is able to detect harmful bacteria in ... When bacteria metabolises inside a wound molecules of that bacteria ...
... Australia's policy of restricting antibiotic use in food-producing animals ... found in its citizens, according to an article in ... available online. , Campylobacter jejuni is a leading ... resistance can make Campylobacter infections difficult for physicians to ...
Cached Biology News:Wound monitor 'sniffs out' infections 2Less antibiotic use in food animals leads to less drug resistance in people, study shows 2
... Specialty Chemistries, QC, Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs of Abuse, and Industrial ... ... ... ...
... System creates isogenic cell lines all ... the protein of interest. This homogeneous ... In this experiment the coding sequence ... into pcDNA5/FRT and transfected into Flp-In-293 ...
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
Biology Products: